Horizon Therapeutics Public Limited Company [NASDAQ: HZNP] closed the trading session at $95.41 on 07/13/21. The day’s price range saw the stock hit a low of $94.50, while the highest price level was $96.68. The company report on July 8, 2021 that Horizon Therapeutics plc to Release Second-Quarter 2021 Financial Results and Host Webcast on Aug. 4, 2021.
Horizon Therapeutics plc (Nasdaq: HZNP) announced that its second-quarter 2021 financial results will be released on Wednesday, Aug. 4, 2021. Following the announcement, Horizon’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.
The live webcast and a replay may be accessed at http://ir.horizontherapeutics.com. Please connect to the Company’s website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. A replay of the webcast will be available approximately two hours after the live webcast.
The stocks have a year to date performance of 30.43 percent and weekly performance of -0.39 percent. The stock has been moved at 21.25 percent over the last six months. The stock has performed 2.27 percent around the most recent 30 days and changed 4.14 percent over the most recent 3-months.
If compared to the average trading volume of 1.57M shares, HZNP reached to a volume of 1479102 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Horizon Therapeutics Public Limited Company [HZNP]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for HZNP shares is $114.18 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on HZNP stock is a recommendation set at 1.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Horizon Therapeutics Public Limited Company shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on March 22, 2021. While these analysts kept the previous recommendation, Wolfe Research raised their target price to Outperform. The new note on the price target was released on March 12, 2021, representing the official price target for Horizon Therapeutics Public Limited Company stock. Previously, the target price had yet another raise to $110, while JP Morgan analysts kept a Overweight rating on HZNP stock.
The Average True Range (ATR) for Horizon Therapeutics Public Limited Company is set at 2.56, with the Price to Sales ratio for HZNP stock in the period of the last 12 months amounting to 9.55. The Price to Book ratio for the last quarter was 5.54, with the Price to Cash per share for the same quarter was set at 3.71. Price to Free Cash Flow for HZNP in the course of the last twelve months was 38.30 with Quick ratio for the last quarter at 2.10.
HZNP stock trade performance evaluation
Horizon Therapeutics Public Limited Company [HZNP] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.39. With this latest performance, HZNP shares gained by 2.27% in over the last four-week period, additionally plugging by 21.25% over the last 6 months – not to mention a rise of 70.83% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HZNP stock in for the last two-week period is set at 54.92, with the RSI for the last a single of trading hit 55.02, and the three-weeks RSI is set at 54.51 for Horizon Therapeutics Public Limited Company [HZNP]. The present Moving Average for the last 50 days of trading for this stock 92.36, while it was recorded at 94.63 for the last single week of trading, and 83.89 for the last 200 days.
Horizon Therapeutics Public Limited Company [HZNP]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Horizon Therapeutics Public Limited Company [HZNP] shares currently have an operating margin of +24.37 and a Gross Margin at +75.79. Horizon Therapeutics Public Limited Company’s Net Margin is presently recorded at +17.71.
Return on Total Capital for HZNP is now 12.38, given the latest momentum, and Return on Invested Capital for the company is 9.01. Return on Equity for this stock inclined to 12.55, with Return on Assets sitting at 7.42. When it comes to the capital structure of this company, Horizon Therapeutics Public Limited Company [HZNP] has a Total Debt to Total Equity ratio set at 26.10. Additionally, HZNP Total Debt to Total Capital is recorded at 20.70, with Total Debt to Total Assets ending up at 17.30. Long-Term Debt to Equity for the company is recorded at 26.00, with the Long-Term Debt to Total Capital now at 20.62.
Reflecting on the efficiency of the workforce at the company, Horizon Therapeutics Public Limited Company [HZNP] managed to generate an average of $279,424 per employee. Receivables Turnover for the company is 4.12 with a Total Asset Turnover recorded at a value of 0.42.Horizon Therapeutics Public Limited Company’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.10 and a Current Ratio set at 2.40.
Earnings per share (EPS) analysis for Horizon Therapeutics Public Limited Company [HZNP] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for HZNP. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Horizon Therapeutics Public Limited Company go to 14.00%.
Horizon Therapeutics Public Limited Company [HZNP]: Insider Ownership positions
There are presently around $19,125 million, or 90.50% of HZNP stock, in the hands of institutional investors. The top three institutional holders of HZNP stocks are: VANGUARD GROUP INC with ownership of 20,504,397, which is approximately 2.932% of the company’s market cap and around 0.70% of the total institutional ownership; BLACKROCK INC., holding 15,377,169 shares of the stock with an approximate value of $1.47 billion in HZNP stocks shares; and FMR LLC, currently with $1.33 billion in HZNP stock with ownership of nearly 5.18% of the company’s market capitalization.
Positions in Horizon Therapeutics Public Limited Company stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 268 institutional holders increased their position in Horizon Therapeutics Public Limited Company [NASDAQ:HZNP] by around 18,174,066 shares. Additionally, 266 investors decreased positions by around 18,269,658 shares, while 45 investors held positions by with 164,007,416 shares. The mentioned changes placed institutional holdings at 200,451,140 shares, according to the latest SEC report filing. HZNP stock had 83 new institutional investments in for a total of 3,354,619 shares, while 76 institutional investors sold positions of 1,607,886 shares during the same period.